Financials in USD. Standardized financial statements.
A compact view of how Newron Pharmaceuticals S.p.A. turns revenue into operating income and net income.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $51.39M | $9.06M | $6.09M | $5.76M | $5.26M | $7.04M | $4.03M | $13.43M | $6.73M | $2.38M |
| Revenue Growth? | +467.4% | +48.6% | +5.8% | +9.6% | -25.3% | +74.9% | -70.0% | +99.6% | +182.6% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $295,000 | $1.43M | $1.37M | $0 | $2.63M | $1.26M |
| Gross Profit? | $51.39M | $9.06M | $6.09M | $5.76M | $4.96M | $5.61M | $2.65M | $13.43M | $4.09M | $1.12M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +94.4% | +79.8% | +65.9% | +100.0% | +60.8% | +47.0% |
| Operating Expenses? | $25.22M | $20.69M | $19.68M | $17.78M | $22.70M | $26.82M | $19.12M | $18.85M | $22.04M | $27.49M |
| Operating Income? | $26.17M | -$11.63M | -$13.30M | -$12.36M | -$18.07M | -$20.90M | -$14.98M | -$4.10M | -$15.32M | -$17.68M |
| EBITDA? | $25.94M | -$11.83M | -$13.32M | -$11.76M | -$17.16M | -$19.38M | -$14.79M | -$4.05M | -$15.29M | -$17.60M |
| Income Before Tax | $21.39M | -$16.20M | -$17.47M | -$14.88M | -$19.62M | -$20.16M | -$15.02M | -$5.30M | -$15.20M | -$24.98M |
| Income Tax Expense | $5.55M | $24,000 | $21,000 | $17,000 | $1.38M | $45,000 | $16,000 | -$19,000 | $33,000 | -$2.17M |
| Net Income? | $15.84M | -$16.22M | -$17.49M | -$14.90M | -$21.00M | -$20.21M | -$15.04M | -$5.28M | -$15.24M | -$22.82M |
| EPS? | $0.85 | $-0.91 | $-0.98 | $-0.84 | $-1.18 | $-1.13 | $-0.84 | $-0.32 | $-1.04 | $-1.66 |
| Diluted EPS? | $0.85 | $-0.91 | $-0.98 | $-0.84 | $-1.18 | $-1.13 | $-0.84 | $-0.32 | $-1.04 | $-1.66 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality